---
title: "Jefferies Sticks to Their Buy Rating for Kissei Pharmaceutical Co (KSPHF)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284995207.md"
description: "Jefferies analyst Miyabi Yamakita has maintained a Buy rating for Kissei Pharmaceutical Co (KSPHF) with a price target of Yen5,400.00, while the shares closed at Yen4,320.00. The analyst has a 1.6% average return and a 48.48% success rate, focusing on the Healthcare sector. The consensus rating for Kissei is a Moderate Buy, with an average price target of Yen5,499.13."
datetime: "2026-05-03T12:26:19.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284995207.md)
  - [en](https://longbridge.com/en/news/284995207.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284995207.md)
generator: "portal-rs"
---

# Jefferies Sticks to Their Buy Rating for Kissei Pharmaceutical Co (KSPHF)

In a report released on May 1, Miyabi Yamakita from Jefferies maintained a Buy rating on Kissei Pharmaceutical Co, with a price target of Yen5,400.00. The company’s shares closed last Friday at Yen4,320.00.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

According to TipRanks, Yamakita is a 2-star analyst with an average return of 1.6% and a 48.48% success rate. Yamakita covers the Healthcare sector, focusing on stocks such as Kissei Pharmaceutical Co, Medipal Holdings, and SanBio Co.

Currently, the analyst consensus on Kissei Pharmaceutical Co is a Moderate Buy with an average price target of Yen5,499.13.

### Related Stocks

- [4547.JP](https://longbridge.com/en/quote/4547.JP.md)
- [JEF.US](https://longbridge.com/en/quote/JEF.US.md)
- [7459.JP](https://longbridge.com/en/quote/7459.JP.md)
- [4592.JP](https://longbridge.com/en/quote/4592.JP.md)

## Related News & Research

- [Kissei Pharmaceutical Swings to Operating Loss but Lifts Payouts and Eyes Profit Recovery](https://longbridge.com/en/news/285902787.md)
- [Kissei Pharmaceutical (TSE:4547) One Off Gain Lifts Margin And Tests Bullish Earnings Narrative](https://longbridge.com/en/news/286077464.md)
- [US families, healthcare providers under strain after Trump crackdown on Haitian immigrants](https://longbridge.com/en/news/296335867.md)
- [Jefferies Keeps Their Buy Rating on LEG Immobilien (0QC9)](https://longbridge.com/en/news/296664311.md)
- [Jefferies Sticks to Their Buy Rating for Abbott Laboratories (ABT)](https://longbridge.com/en/news/296645903.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**